Posts

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

/by

Authors: Antony J. Mersiades, Annette Tognela, Paul S. Haber, Martin Stockler, Nicholas Lintzeris, et al
BMJ open, 12 September 2018
—
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, si…

Read more

Dangerous plants in dermatology: Legal and controlled.

/by

Authors: Deeptej Singh, Juliya Fisher, Devorah Shagalov, Aakaash Varma, Daniel M. Siegel
Clinics in Dermatology, May-June 2018
—
The plant and mushroom kingdoms have species used for intoxication, inebriation, or recreation. Some of these species are toxic. Given that many of these plants or substances are illegal and have histories of abuse, much of the research regarding therapeutic application is bas…

Read more

Phytocannabinoids and epilepsy

/by

Authors: R. G. dos Santos, J. E. C. Hallak, J. P. Leite, A. W. Zuardi, J. A. S. Crippa
Journal of Clinical Pharmacy and Therapeutics, April 2015
—
WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…

Read more

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

/by

Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014
—
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…

Read more

The case for assessing cannabidiol in epilepsy

/by

Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014
—
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…

Read more

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

/by

Authors: John Peter Zajicek, Jeremy C. Hobart, Anita Slade, David Barnes, Paul G. Mattison
Journal of Neurology, Neurosurgery, & Psychiatry, November 2012
—
OBJECTIVE: Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of pr…

Read more

Cannabis use amongst patients with inflammatory bowel disease.

/by

Authors: Simon Lal, Neeraj Prasad, Manijeh Ryan, Sabrena Tangri, Mark Silverberg, et al
European Journal of Gastroenterology & Hepatology, October 2011
—
BACKGROUND: Experimental evidence suggests the endogenous cannabinoid system may protect against colonic inflammation, leading to the possibility that activation of this system may have a therapeutic role in inflammatory bowel disease (IBD). Medicinal use of cannabis for chron…

Read more

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

/by

Authors: Ethan B. Russo
British Journal of Pharmacology, August 2011
—
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated…

Read more

Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

/by

Authors: Gregory T. Carter, Aaron M. Flanagan, Mitchell Earleywine, Donald I. Abrams, et al
American Journal of Hospice and Palliative Medicine, August 2011
—
Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I…

Read more

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

/by

Authors: Ethan B. Russo, Geoffrey W. Guy, Philip J. Robson
Chemistry & Biodiversity, August 2007
—
Cannabis sativa L. has been utilized for treatment of pain and sleep disorders since ancient times. This review examines modern studies on effects of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep. It goes on to report new information on the effects on sleep…

Read more

Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’.

/by

Authors: Rachel E. Westfall, Patricia A. Janssen, Philippe Lucas, Rielle Capler
Complementary Therapies in Clinical Practice, February 2006
—
A majority of women experience some nausea and/or vomiting during pregnancy. This condition can range from mild nausea to extreme nausea and vomiting, with 1-2% of women suffering from the life-threatening condition hyperemesis gravidarum. Cannabis (Cannabis sativa) may be use…

Read more